Robert Wasserman

2.4k total citations
35 papers, 1.8k citations indexed

About

Robert Wasserman is a scholar working on Immunology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Robert Wasserman has authored 35 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 13 papers in Public Health, Environmental and Occupational Health and 12 papers in Molecular Biology. Recurrent topics in Robert Wasserman's work include Acute Lymphoblastic Leukemia research (13 papers), T-cell and B-cell Immunology (9 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Robert Wasserman is often cited by papers focused on Acute Lymphoblastic Leukemia research (13 papers), T-cell and B-cell Immunology (9 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Robert Wasserman collaborates with scholars based in United States, Spain and Canada. Robert Wasserman's co-authors include Richard R. Hardy, G Rovera, B A Reichard, S Shane, Kyoko Hayakawa, Masao Yamada, A J Caton, Beverly J. Lange, Richard B. Womer and Naomi Galili and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Robert Wasserman

32 papers receiving 1.8k citations

Peers

Countries citing papers authored by Robert Wasserman

Since Specialization

Citations

This map shows the geographic impact of Robert Wasserman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Wasserman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Wasserman more than expected).

Fields of papers citing papers by Robert Wasserman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Wasserman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Wasserman. The network helps show where Robert Wasserman may publish in the future.

Co-authorship network of co-authors of Robert Wasserman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Wasserman. A scholar is included among the top collaborators of Robert Wasserman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Wasserman. Robert Wasserman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling 2005 ·Molecular Cancer Therapeutics ·James S. Hardwick, Yi Yang, Chunsheng Zhang, Bin Shi, Rosemary C. McFall, Elizabeth J. Koury, Susan L. Hill, Hongyue Dai, Robert Wasserman, Robert L. Phillips, Edward J. Weinstein, Nancy E. Kohl, Michael E. Severino, John Lamb, Laura Sepp‐Lorenzino	24
2	Rapamycin is active against B-precursor leukemiain vitroandin vivo, an effect that is modulated by IL-7-mediated signaling 2003 ·Proceedings of the National Academy of Sciences ·Valerie I. Brown, (unknown), (unknown), (unknown), (unknown), Robert Wasserman, Stephan A. Grupp	134
3	Cytoplasmic micro heavy chain confers sensitivity to dexamethasone-induced apoptosis in early B-lineage acute lymphoblastic leukemia. 2002 ·PubMed ·(unknown), (unknown), Susan R. Rheingold, Richard Aplenc, Robert Wasserman, Stephan A. Grupp	7
4	Response by B Cell Precursors to Pre-B Receptor Assembly: Differences Between Fetal Liver and Bone Marrow 2000 ·Current topics in microbiology and immunology ·Richard R. Hardy, Robert Wasserman, (unknown), Susan A. Shinton, Kyoko Hayakawa	8
5	A Novel Mechanism for B Cell Repertoire Maturation Based on Response by B Cell Precursors to Pre–B Receptor Assembly 1998 ·The Journal of Experimental Medicine ·Robert Wasserman, (unknown), Susan A. Shinton, Condie E. Carmack, Tim Manser, David L. Wiest, Kyoko Hayakawa, Richard R. Hardy	99
6	The Evolution of B Precursor Leukemia in the Eμ-ret Mouse 1998 ·Blood ·Robert Wasserman, (unknown), Richard R. Hardy	38
7	B Lymphocyte Developmental Lineages 1997 ·Annals of the New York Academy of Sciences ·Kyoko Hayakawa, Yuesheng Li, Robert Wasserman, (unknown), Susan A. Shinton, Richard R. Hardy	23
8	The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors 1997 ·Gene ·L R Finger, Jeffrey J. Pu, Robert Wasserman, Rajeev Vibhakar, E. Louie, Richard R. Hardy, Peter D. Burrows, L G Billips	92
9	Down-regulation of terminal deoxynucleotidyl transferase by Ig heavy chain in B lineage cells 1997 ·The Journal of Immunology ·Robert Wasserman, (unknown), (unknown)	49
10	Identification of the Earliest B Lineage Stage in Mouse Bone Marrow 1996 ·Immunity ·(unknown), Robert Wasserman, Kyoko Hayakawa, Richard R. Hardy	308
11	Differential expression of the blk and ret tyrosine kinases during B lineage development is dependent on Ig rearrangement 1995 ·The Journal of Immunology ·Robert Wasserman, (unknown), Russell Hardy	40
12	Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. 1993 ·Journal of Clinical Oncology ·(unknown), Robert Wasserman, Naomi Galili, B A Reichard, S Shane, Beverly J. Lange, G Rovera	45
13	The pattern of joining (JH) gene usage in the human IgH chain is established predominantly at the B precursor cell stage 1992 ·The Journal of Immunology ·Robert Wasserman, Yoshiaki Ito, Naomi Galili, (unknown), B A Reichard, S Shane, Beverly J. Lange, G Rovera	28
14	Predominance of fetal type DJH joining in young children with B precursor lymphoblastic leukemia as evidence for an in utero transforming event. 1992 ·The Journal of Experimental Medicine ·Robert Wasserman, Naomi Galili, Yoshiaki Ito, B A Reichard, S Shane, G Rovera	65
15	Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. 1992 ·Journal of Clinical Oncology ·Robert Wasserman, Naomi Galili, (unknown), Jeffrey H. Silber, B A Reichard, S Shane, Richard B. Womer, Beverly J. Lange, G Rovera	80
16	VH gene rearrangement events can modify the immunoglobulin heavy chain during progression of B-lineage acute lymphoblastic leukemia [see comments] 1992 ·Blood ·Robert Wasserman, (unknown), (unknown), (unknown), (unknown), S Shane, B Lange, G Rovera	1
17	Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. 1991 ·The Journal of Experimental Medicine ·Masao Yamada, Robert Wasserman, B A Reichard, S Shane, A J Caton, G Rovera	333
18	Minimal Residual Disease in Childhood B-Lineage Lymphoblastic Leukemia 1990 ·New England Journal of Medicine ·Masao Yamada, Robert Wasserman, Beverly J. Lange, B A Reichard, Richard B. Womer, G Rovera	163
19	Fibrosarcoma in a child with neurofibromatosis 1989 ·Medical and Pediatric Oncology ·Giulio J. D’Angio, Audrey E. Evans, Robert Wasserman	1
20	Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas. 1982 ·The Journal of Experimental Medicine ·Nicholas Chiorazzi, Robert Wasserman, Henry G. Kunkel	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact